PL365170A1 - N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases - Google Patents

N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases

Info

Publication number
PL365170A1
PL365170A1 PL01365170A PL36517001A PL365170A1 PL 365170 A1 PL365170 A1 PL 365170A1 PL 01365170 A PL01365170 A PL 01365170A PL 36517001 A PL36517001 A PL 36517001A PL 365170 A1 PL365170 A1 PL 365170A1
Authority
PL
Poland
Prior art keywords
oxazolyl
thiazolyl
thio
alkyl
methyl
Prior art date
Application number
PL01365170A
Other languages
English (en)
Polish (pl)
Inventor
Raj N. Misra
Hai-Yun Xiao
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/727,957 external-priority patent/US6515004B1/en
Priority claimed from US09/746,060 external-priority patent/US6414156B2/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of PL365170A1 publication Critical patent/PL365170A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
PL01365170A 2000-07-26 2001-05-09 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases PL365170A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61662700A 2000-07-26 2000-07-26
US09/727,957 US6515004B1 (en) 1999-12-15 2000-12-01 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
US09/746,060 US6414156B2 (en) 1998-10-21 2000-12-22 Process for preparing azacycloalkanoylaminothiazoles

Publications (1)

Publication Number Publication Date
PL365170A1 true PL365170A1 (en) 2004-12-27

Family

ID=27417184

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365170A PL365170A1 (en) 2000-07-26 2001-05-09 N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases

Country Status (26)

Country Link
EP (1) EP1303513A1 (sl)
JP (1) JP2004509857A (sl)
KR (1) KR20030016429A (sl)
CN (1) CN100457753C (sl)
AR (1) AR030563A1 (sl)
AU (1) AU2001259704A1 (sl)
BG (1) BG65132B1 (sl)
BR (1) BR0112674A (sl)
CA (1) CA2417254A1 (sl)
CZ (1) CZ2003237A3 (sl)
EE (1) EE200300041A (sl)
EG (1) EG24409A (sl)
GE (1) GEP20043367B (sl)
HR (1) HRP20030116A2 (sl)
HU (1) HUP0303698A2 (sl)
IL (2) IL153591A0 (sl)
LV (1) LV13037B (sl)
MX (1) MXPA03000774A (sl)
MY (1) MY129635A (sl)
NO (1) NO20030394L (sl)
PL (1) PL365170A1 (sl)
SI (1) SI21099A (sl)
SK (1) SK18392002A3 (sl)
TW (1) TWI302533B (sl)
WO (1) WO2002010162A1 (sl)
YU (1) YU4903A (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
EP2311818B1 (en) * 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
PT1537116E (pt) 2002-09-04 2010-09-03 Schering Corp Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
KR20050057072A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
KR20050057520A (ko) 2002-09-23 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 이미다조피라진
WO2004026310A1 (en) 2002-09-23 2004-04-01 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
EP1555264A1 (en) * 2004-01-15 2005-07-20 Sireen AG Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase.
DE102005008310A1 (de) * 2005-02-17 2006-08-24 Schering Ag Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle
JP2009504756A (ja) * 2005-08-17 2009-02-05 シェーリング コーポレイション 新規な高親和性のチオフェンベースおよびフランベースのキナーゼリガンド
ES2349476T3 (es) 2005-09-09 2011-01-03 Schering Corporation Nuevos derivados de 4-ciano, 4-amino y 4-aminometilo de compuestos de pirazolo[1,5-a]piridinas, pirazolo[1,5-c]pirimidinas y 2h-indazol y derivados de 5-ciano, 5-amino y 5-aminometilo de compuestos de imidazo[1,2-a]piridinas e imidazo[1,5-a]pirazinas, como inhibidores de cinasa dependiente de ciclina.
EP1931676B1 (en) 2005-10-06 2011-11-16 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
EP2044066A2 (en) * 2006-06-06 2009-04-08 Bristol-Myers Squibb Company Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide
WO2008054749A1 (en) 2006-10-31 2008-05-08 Schering Corporation 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
WO2008054702A1 (en) 2006-10-31 2008-05-08 Schering Corporation Anilinopiperazine derivatives and methods of use thereof
CA2686848A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
WO2010075542A1 (en) 2008-12-23 2010-07-01 Curis, Inc. Cdk inhibitors
WO2011025706A2 (en) 2009-08-26 2011-03-03 Schering Corporation Heterocyclic amide compounds as protein kinase inhibitors
US20150051227A1 (en) 2012-03-30 2015-02-19 Merck Sharp & Dohme Corp. Predictive biomarker useful for cancer therapy mediated by a cdk inhibitor
CN104693256B (zh) * 2013-12-04 2018-07-10 杭州源昶医药科技有限公司 吉西他滨衍生物、含该衍生物的组合物及所述衍生物的制药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US6262096B1 (en) * 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
ATE288904T1 (de) * 1998-06-18 2005-02-15 Bristol Myers Squibb Co Durch kohlenstoff substituierte aminothiazole als inhibitoren von zyclin-abhägigen kinasen
US6414156B2 (en) * 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
MY125768A (en) * 1999-12-15 2006-08-30 Bristol Myers Squibb Co N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
GEP20043367B (en) 2004-06-10
LV13037B (en) 2003-11-20
IL153591A0 (en) 2003-07-06
BG107468A (en) 2004-01-30
TWI302533B (en) 2008-11-01
WO2002010162A1 (en) 2002-02-07
IL153591A (en) 2009-07-20
SI21099A (sl) 2003-06-30
SK18392002A3 (sk) 2003-09-11
NO20030394D0 (no) 2003-01-24
HUP0303698A2 (hu) 2004-04-28
MY129635A (en) 2007-04-30
CZ2003237A3 (cs) 2003-06-18
EP1303513A1 (en) 2003-04-23
AU2001259704A1 (en) 2002-02-13
CN100457753C (zh) 2009-02-04
HRP20030116A2 (en) 2005-02-28
MXPA03000774A (es) 2003-09-10
BG65132B1 (bg) 2007-03-30
CA2417254A1 (en) 2002-02-07
KR20030016429A (ko) 2003-02-26
CN1444584A (zh) 2003-09-24
AR030563A1 (es) 2003-08-27
EG24409A (en) 2009-05-20
JP2004509857A (ja) 2004-04-02
YU4903A (sh) 2006-03-03
NO20030394L (no) 2003-03-03
BR0112674A (pt) 2003-12-30
EE200300041A (et) 2005-04-15

Similar Documents

Publication Publication Date Title
EG24409A (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases
HK1049661B (zh) 細胞周期蛋白依賴激酶的n-[5-[[[5-烷基-2-噁唑基]甲基]硫代]-2-噻唑基]酰胺抑制劑
HK1049662A1 (zh) 細胞周期蛋白依賴激酶氨基噻唑抑制劑
HUP0300974A3 (en) N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases, pharmaceutical compositions containing them and their use
EG24028A (en) Aminothiazole inhibitors of cyclin dependent kinases
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AP1967A (en) Thiazolidinone compounds as inhibitors of Hyak3
HU0304052D0 (en) Heterocyclic inhibitors of erk2 and uses thereof
AU2002350228A1 (en) Antisense modulation of myd88 expression
AU2001216218A1 (en) Heterocyclic analgesic compounds and method of use thereof
GB0015904D0 (en) Inhibitors of HPV E1 helicase enzyme
AU2001229727A1 (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
IL137929A0 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
AU2001259990A1 (en) Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
AU2002358874A1 (en) 2-amino-4-heteroarylethyl thiazoline derivatives and their use an inhibitors of inducible no-synthase
AU2001245741A1 (en) Antisense inhibition of adam10 expression
IL152792A0 (en) Heterocycle derivatives and methods of use
AU2002214038A1 (en) Inhibitors of transglutaminases
AU2002212162A1 (en) Incompetitive inhibitors of helicase primase
IS6696A (is) N-[5-[[[5-alkýl-2-oxazólýl]metýl]þíó]-2-þíazólýl]karboxamíð tálmar sýklínháðra kínasa
AU1212002A (en) Use of lipase inhibitors
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2002310077A1 (en) Thiazole compounds useful as inhibitors of protein kinases
AU2002212172A1 (en) Novel mmp-2 derivatives for use as inhibitors of integrin alphavbeta3
GB0000329D0 (en) Semiochemical capable of effecting gene expression

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)